Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies
- PMID: 17433322
- DOI: 10.1053/j.gastro.2007.02.055
Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies
Abstract
Background & aims: Following the world's first successful implementation of a universal hepatitis B virus (HBV) vaccination program for infants in Taiwan 20 years ago, we performed this study to evaluate the long-term protection afforded by HBV vaccination and to rationalize further prevention strategies.
Methods: HBV seromarkers, including hepatitis B surface antigen (HBsAg) and antibodies to HBsAg (anti-HBs) and core antigen (anti-HBc), were studied in 18,779 subjects from neonates to adults below 30 years of age in 2004. The birth cohort effect was evaluated by comparing the results of the same birth cohorts at different ages among this survey and the previous 1984, 1989, 1994, and 1999 surveys.
Results: The seropositive rates for HBsAg, anti-HBs, and anti-HBc were 1.2%, 50.5%, and 3.7%, respectively, in those born after the vaccination program (<20 years of age) in 2004. A positive maternal HBsAg status was found in 89% of the HBsAg seropositive subjects born after the vaccination program. The absence of an increase in HBsAg seropositive subjects at different ages in the same birth cohorts born after the vaccination program implied no increased risk of persistent HBV infection with aging.
Conclusions: Universal HBV vaccination provides long-term protection up to 20 years, and a universal booster is not indicated for the primary HBV vaccinees before adulthood. Maternal transmission is the primary reason for vaccine failure and is the challenge that needs to be addressed in future vaccination programs. This may include an appropriate hepatitis B immunoglobulin administration strategy for high-risk infants and involve efforts to minimize noncompliance.
Similar articles
-
Hepatitis B vaccination in children: the Taiwan experience.Pathol Biol (Paris). 2010 Aug;58(4):296-300. doi: 10.1016/j.patbio.2009.11.002. Epub 2010 Jan 29. Pathol Biol (Paris). 2010. PMID: 20116181
-
Seroprevalence of Hepatitis-B infection amongst Taiwanese university students 18 years following the commencement of a national Hepatitis-B vaccination program.J Med Virol. 2007 Feb;79(2):138-43. doi: 10.1002/jmv.20771. J Med Virol. 2007. PMID: 17177303
-
Minimization of hepatitis B infection by a 25-year universal vaccination program.J Hepatol. 2012 Oct;57(4):730-5. doi: 10.1016/j.jhep.2012.05.021. Epub 2012 Jun 2. J Hepatol. 2012. PMID: 22668640
-
Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period.Intervirology. 2010;53(1):20-8. doi: 10.1159/000252780. Epub 2010 Jan 5. Intervirology. 2010. PMID: 20068337 Review.
-
Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.Epidemiol Rev. 2006;28:126-35. doi: 10.1093/epirev/mxj010. Epub 2006 Jun 16. Epidemiol Rev. 2006. PMID: 16782778 Review.
Cited by
-
Hepatitis B Vaccine: Four Decades on.Vaccines (Basel). 2024 Apr 18;12(4):439. doi: 10.3390/vaccines12040439. Vaccines (Basel). 2024. PMID: 38675820 Free PMC article. Review.
-
Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030.Vaccines (Basel). 2024 Mar 9;12(3):288. doi: 10.3390/vaccines12030288. Vaccines (Basel). 2024. PMID: 38543922 Free PMC article. Review.
-
Post-Vaccination and Post-Infection Immunity to the Hepatitis B Virus and Circulation of Immune-Escape Variants in the Russian Federation 20 Years after the Start of Mass Vaccination.Vaccines (Basel). 2023 Feb 13;11(2):430. doi: 10.3390/vaccines11020430. Vaccines (Basel). 2023. PMID: 36851307 Free PMC article.
-
Recent Advances in Protective Vaccines against Hepatitis Viruses: A Narrative Review.Viruses. 2023 Jan 12;15(1):214. doi: 10.3390/v15010214. Viruses. 2023. PMID: 36680254 Free PMC article. Review.
-
Mathematical analysis of a new nonlinear stochastic hepatitis B epidemic model with vaccination effect and a case study.Eur Phys J Plus. 2022;137(5):558. doi: 10.1140/epjp/s13360-022-02748-x. Epub 2022 May 6. Eur Phys J Plus. 2022. PMID: 35542829 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical